AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31836609 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib 240 mg b.i.d.
Number of subjects: 28
Study 28703440 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education for 35 participants for 60 minutes
Number of subjects: 70
Study 28703440 — intervention group
Group type: COMPARATOR
Intervention: Standardized materials for 35 participants for 20 minutes
Number of subjects: 70
Study 28473524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed deprescribing brochure on benzodiazepines
Number of subjects: 261
Study 26163281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateralized RSA
Number of subjects: 34
Study 26163281 — intervention group
Group type: COMPARATOR
Intervention: Non-lateralized RSA
Number of subjects: 34
Study 26163281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 23252791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pineapple
Number of subjects: 30
Study 23252791 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana
Number of subjects: 30
Study 23252791 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange
Number of subjects: 30
Study 20970117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 43
Study 20970117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive DBT training
Number of subjects: 43
Study 20970117 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional six months of DBT
Number of subjects: 43
Study 20970117 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 43
Study 17919346 — intervention group
Group type: EXPERIMENTAL
Intervention: Himalaya 292 foods
Number of subjects: 17
Study 16325898 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sunscreen use
Number of subjects: 1621
Study 16325898 — intervention group
Group type: COMPARATOR
Intervention: Discretionary sunscreen use
Number of subjects: 1621
Study 12843357 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stroke patients
Number of subjects: 48
Study 12843357 — intervention group
Group type: EXPERIMENTAL
Intervention: Common haplotype A-G-8/12-C
Number of subjects: 48
Study 10068383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 10068383 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 307
Study 10068383 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus cyclic medroxyprogesterone acetate (MPA)
Number of subjects: 307
Study 10068383 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus daily MPA
Number of subjects: 307
Study 10068383 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus cyclic micronized progesterone (MP)
Number of subjects: 307
Study 8843810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 18
Study 8843810 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 18
Study 8843810 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malaria
Number of subjects: 18
Study 8843810 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of PMNS
Number of subjects: 18
Study 1704026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold glucose solution (5 degrees C)
Number of subjects: 15
Study 1704026 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm glucose solution (50 degrees C)
Number of subjects: 15
Study 1704026 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 15
Study 6660202 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture on the normal side (including points Chu‐chih (LI‐11), Shou‐son‐li (LI‐10), Wai‐kuan (TH‐5), Ho‐ku (LI‐4), Yang‐chih (TH‐4)) followed by rehabilitation (Reha) of the lesion.
Number of subjects: 0
Study 6660202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of Reha of the lesion with acupuncture on the abnormal side (including points Chu‐chih (LI‐11), Shou‐san‐li (LI‐10), Wai‐kuan (TH‐5), Ho‐ku (LI‐4), Yang‐chih (TH‐4)).
Number of subjects: 0
Study 6660202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple treatment with Reha on the abnormal side.
Number of subjects: 0
Study 6660202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple treatment with acupuncture on the abnormal side.
Number of subjects: 0
Study 30037491 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 (irinotecan hydrochloride) administered at a dosage of 100 mg/m2 via intravenous infusion on days 1, 8, and 15 of a 4-week cycle, for up to 2 cycles.
Number of subjects: 22
Study 27307314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed chicken liver diet (HZD)
Number of subjects: 10
Study 27307314 — intervention group
Group type: COMPARATOR
Intervention: Hydrolysed poultry feather diet (RCU)
Number of subjects: 10
Study 24642950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened low-fat milk at 10% or 20% of calories
Number of subjects: 65
Study 24642950 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS-sweetened low-fat milk at 10% or 20% of calories
Number of subjects: 65
Study 24642950 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric diet with added sugars (sucrose or HFCS)
Number of subjects: 65
Study 22433300 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75-mg lozenges (test drug)
Number of subjects: 12
Study 22433300 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 8.75-mg lozenges (reference drug)
Number of subjects: 12
Study 20694731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling collar (CC(90))
Number of subjects: 17
Study 20694731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling collar (CC(15))
Number of subjects: 17
Study 20694731 — intervention group
Group type: COMPARATOR
Intervention: Uncooled collar (C(90))
Number of subjects: 17
Study 20694731 — intervention group
Group type: COMPARATOR
Intervention: No collar (NC(90))
Number of subjects: 17
Study 20694731 — intervention group
Group type: COMPARATOR
Intervention: No collar (NC(15))
Number of subjects: 17
Study 17987285 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on the first day and 200 mg twice on the second day)
Number of subjects: 12
Study 17987285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg once on the first day and 200 mg once on the second day)
Number of subjects: 12
Study 17987285 — intervention group
Group type: COMPARATOR
Intervention: Control (5 microg/kg of intravenous fentanyl without pretreatment)
Number of subjects: 12
Study 15782792 — intervention group
Group type: EXPERIMENTAL
Intervention: Right subaxillary muscle-sparing thoracotomy
Number of subjects: 161
Study 15782792 — intervention group
Group type: COMPARATOR
Intervention: Right thoracotomy
Number of subjects: 161
Study 15782792 — intervention group
Group type: COMPARATOR
Intervention: Midline sternotomy
Number of subjects: 161
Study 12391036 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (1 hour cycling)
Number of subjects: 13
Study 12391036 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee ingestion (5 mg caffeine/kg body mass)
Number of subjects: 13
Study 12391036 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee ingestion followed by exercise (1 hour later)
Number of subjects: 13
Study 12391036 — intervention group
Group type: COMPARATOR
Intervention: Control (did nothing)
Number of subjects: 13
Study 11209671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cold stress (16 degrees C)
Number of subjects: 0
Study 11209671 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral conditions (28 degrees C)
Number of subjects: 0
Study 9135468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide administered 90 min prior to barium
Number of subjects: 0
Study 9135468 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice of metoclopramide 5-10 min prior to barium)
Number of subjects: 0
Study 1398229 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (10.8 g)
Number of subjects: 12
Study 1398229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3892172 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid prime containing glucose
Number of subjects: 24
Study 3892172 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid prime containing lactate
Number of subjects: 24
Study 3892172 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid prime containing glucose and lactate
Number of subjects: 24
Study 3892172 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid prime containing neither glucose nor lactate
Number of subjects: 24
Study 31577682 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratification system based on significant risk factors (age, sex, COPD, diabetes, anemia, end-stage renal disease)
Number of subjects: 7582
Study 31577682 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratification system applied to validation cohort
Number of subjects: 7582
Study 30427805 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual attention manipulation (looking toward and away from the hand)
Number of subjects: 20
Study 30427805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive regulation (rest, attenuate MEP amplitude, potentiate MEP amplitude)
Number of subjects: 20
Study 26752327 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic‐smoking Program (PSP)
Number of subjects: 526
Study 26752327 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 526
Study 25352208 — intervention group
Group type: EXPERIMENTAL
Intervention: echocardiographic calcium score (eCS)
Number of subjects: 141
Study 25352208 — intervention group
Group type: EXPERIMENTAL
Intervention: non-coronary cardiac calcium score (nCACS)
Number of subjects: 141
Study 22633178 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and environmental intervention (weekly nutrition and food classes and food environment changes)
Number of subjects: 103
Study 22633178 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 103
Study 20045366 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for 12 months
Number of subjects: 29
Study 20045366 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for 24 months
Number of subjects: 29
Study 20045366 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for >or= 12 months
Number of subjects: 29
Study 20045366 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat (Zavesca) for >or= 1 dose
Number of subjects: 29
Study 18435668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylurea therapy
Number of subjects: 1364
Study 15974563 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib (60 mg, 90 mg, or 120 mg)
Number of subjects: 5441
Study 15974563 — intervention group
Group type: COMPARATOR
Intervention: non-selective NSAIDs (ibuprofen, diclofenac, or naproxen)
Number of subjects: 5441
Study 12644728 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐epi‐prostaglandin F2 alpha (PGF)
Number of subjects: 33
Study 12644728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11379456 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of the TSI-GSD 200 vaccine
Number of subjects: 0
Study 11379456 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two doses of the TSI-GSD 200 vaccine
Number of subjects: 0
Study 11379456 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemagglutination inhibition (HI) test
Number of subjects: 0
Study 11379456 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque reduction neutralisation (PRN) test
Number of subjects: 0
Study 8850763 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinic instruction plus a voucher for a free mammogram
Number of subjects: 0
Study 8850763 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic instruction alone
Number of subjects: 0
Study 1531259 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloroglucinol (40 mg, two ampoules)
Number of subjects: 20
Study 1531259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two ampoules)
Number of subjects: 20
Study 4077795 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine aerosol
Number of subjects: 8
Study 4077795 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline
Number of subjects: 8
Study 31489020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Labetalol
Number of subjects: 124
Study 31489020 — intervention group
Group type: COMPARATOR
Intervention: Oral Nifedipine
Number of subjects: 124
Study 29432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program + exercise program (WL + E group, n = 28)
Number of subjects: 55
Study 26653014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored SMS group
Number of subjects: 150
Study 26653014 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tailored SMS group
Number of subjects: 150
Study 26653014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 24778393 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28)
Number of subjects: 208
Study 24778393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 24778393 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 208
Study 22449317 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 60
Study 22449317 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion
Number of subjects: 60
Study 22449317 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 60
Study 20086031 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (10 mg, oral)
Number of subjects: 14
Study 20086031 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg, intravenous)
Number of subjects: 14
Study 18044335 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (group I)
Number of subjects: 80
Study 18044335 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic cholecystectomy (group II)
Number of subjects: 80
Study 18044335 — intervention group
Group type: COMPARATOR
Intervention: Planned laparoscopic cholecystectomy (control group)
Number of subjects: 80
Study 18955380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of iron
Number of subjects: 16
Study 18955380 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of desferrioxamine
Number of subjects: 16
Study 15468991 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride (25 mg t.i.d. intravenously for 3 days, then orally for 7 days)
Number of subjects: 87
Study 15468991 — intervention group
Group type: EXPERIMENTAL
Intervention: L-sulpiride
Number of subjects: 87
Study 15468991 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with other vestibular suppressants
Number of subjects: 87
Study 11585003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin
Number of subjects: 0
Study 11585003 — intervention group
Group type: COMPARATOR
Intervention: Intravesical bacillus Calmette‐Guerin (BCG)
Number of subjects: 0
Study 9215023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 20
Study 9215023 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 20
Study 7663466 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant design, application, and site of placement
Number of subjects: 2132
Study 3604933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicated Renografin‐76 (1.5 to 2.0 ml)
Number of subjects: 7
Study 3604933 — intervention group
Group type: COMPARATOR
Intervention: Nonsonicated Renografin‐76 (7 to 9 ml)
Number of subjects: 7
Study 31421272 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive tract decontamination (SDD)
Number of subjects: 8665
Study 31421272 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective oropharyngeal decontamination (SOD)
Number of subjects: 8665
Study 31421272 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 8665
Study 30445275 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 150
Study 30445275 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant reductions in smoking
Number of subjects: 150
Study 30445275 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent change in cigarettes smoked (modeled continuously)
Number of subjects: 150
Study 30445275 — intervention group
Group type: COMPARATOR
Intervention: Changes in alcohol use
Number of subjects: 150
Study 27854559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic hormonal contraception (CHC)
Number of subjects: 490
Study 27854559 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal contraception
Number of subjects: 490
Study 26109611 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA-HA screw
Number of subjects: 40
Study 26109611 — intervention group
Group type: COMPARATOR
Intervention: Titanium screw
Number of subjects: 40
Study 25246774 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminaphtone (Capilarema 75 mg) administered twice daily for 5 days
Number of subjects: 30
Study 25246774 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for 5 days
Number of subjects: 30
Study 22047100 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless naming treatment (ENT)
Number of subjects: 8
Study 22047100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestural facilitation of naming (GES)
Number of subjects: 8
Study 19283886 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-B (High Protein at Breakfast)
Number of subjects: 9
Study 19283886 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-L (High Protein at Lunch)
Number of subjects: 9
Study 19283886 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-D (High Protein at Dinner)
Number of subjects: 9
Study 19283886 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-E (High Protein Equally Divided)
Number of subjects: 9
Study 17375492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention dose (number of six possible intervention components completed)
Number of subjects: 1088
Study 17375492 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of four telephone counseling calls
Number of subjects: 1088
Study 15726540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 354
Study 15726540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 11916546 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days)
Number of subjects: 36
Study 11916546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days) plus alpha-interferon 2b (3 million Units/day subcutaneously from day 1 for 5 days)
Number of subjects: 36
Study 9861120 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1 followed by 0.833 microgram kg‐1 min‐1 until dural closure (group Alf.)
Number of subjects: 52
Study 9861120 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1 followed by 0.833 microgram kg‐1 min‐1 for 2 h, then remifentanil 0.25 microgram kg‐1 min‐1 (group Alf.-Remi.)
Number of subjects: 52
Study 9861120 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram kg‐1 followed by 0.5 microgram kg‐1 min‐1 reducing to 0.25 microgram kg‐1 min‐1 after craniotomy (group Remi.)
Number of subjects: 52
Study 7630152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg orally (p.o.)
Number of subjects: 13
Study 7630152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2 micrograms/kg/min intravenously (i.v.)
Number of subjects: 13
Study 7630152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 4 micrograms/kg/min intravenously (i.v.)
Number of subjects: 13
Study 7630152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 6 micrograms/kg/min intravenously (i.v.)
Number of subjects: 13
Study 7630152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine 6 micrograms/kg intravenously (i.v.)
Number of subjects: 13
Study 2705719 — intervention group
Group type: EXPERIMENTAL
Intervention: Polybutester (Novafil, Davis & Geck)
Number of subjects: 0
Study 2705719 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE (Gore‐tex, W L Gore)
Number of subjects: 0
Study 2705719 — intervention group
Group type: COMPARATOR
Intervention: Nylon (Ethilon, Ethicon UK)
Number of subjects: 0
Study 937355 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 15 mg
Number of subjects: 12
Study 937355 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine hydrochloride 100 mg
Number of subjects: 12
Study 937355 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 60 mg
Number of subjects: 12
Study 30682144 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Tape (ET)
Number of subjects: 13
Study 30682144 — intervention group
Group type: COMPARATOR
Intervention: Sham Tape (ST)
Number of subjects: 13
Study 28068440 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided custom ablation (TCAT)
Number of subjects: 30
Study 28068440 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) ablation
Number of subjects: 30
Study 25299740 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel filler augmentation of the tear trough
Number of subjects: 12
Study 25299740 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid gel augmentation of the cheek
Number of subjects: 12
Study 25299740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tear trough and cheek treated
Number of subjects: 12
Study 25299740 — intervention group
Group type: COMPARATOR
Intervention: Both sides treated (tear trough and cheek)
Number of subjects: 12
Study 23280399 — intervention group
Group type: EXPERIMENTAL
Intervention: Full AMIGAS program with video (n = 151)
Number of subjects: 613
Study 23280399 — intervention group
Group type: EXPERIMENTAL
Intervention: AMIGAS program without video (n = 154)
Number of subjects: 613
Study 23280399 — intervention group
Group type: EXPERIMENTAL
Intervention: AMIGAS program without flip chart (n = 155)
Number of subjects: 613
Study 23280399 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n = 153)
Number of subjects: 613